Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gains from Sales and Divestitures (2020 - 2022)

Mirum Pharmaceuticals has reported Gains from Sales and Divestitures over the past 3 years, most recently at $122464.0 for Q4 2022.

  • Quarterly results put Gains from Sales and Divestitures at $122464.0 for Q4 2022, down 8.33% from a year ago — trailing twelve months through Dec 2022 was $122464.0 (down 8.33% YoY), and the annual figure for FY2022 was $122464.0, down 8.33%.
  • Gains from Sales and Divestitures for Q4 2022 was $122464.0 at Mirum Pharmaceuticals, up from $100194.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for MIRM hit a ceiling of $133593.0 in Q4 2020 and a floor of $33396.0 in Q1 2021.
  • Median Gains from Sales and Divestitures over the past 3 years was $50098.0 (2021), compared with a mean of $71435.0.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 199.99% in 2021 and later decreased 8.33% in 2022.
  • Mirum Pharmaceuticals' Gains from Sales and Divestitures stood at $133593.0 in 2020, then changed by 0.0% to $133593.0 in 2021, then dropped by 8.33% to $122464.0 in 2022.
  • The last three reported values for Gains from Sales and Divestitures were $122464.0 (Q4 2022), $100194.0 (Q3 2022), and $66796.0 (Q2 2022) per Business Quant data.